The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Alemtuzumab for patients with chronic lymphocytic leukaemia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, February 2012
|
| DOI | 10.1002/14651858.cd008078.pub2 |
| Pubmed ID | |
| Authors |
Nicole Skoetz, Kathrin Bauer, Thomas Elter, Ina Monsef, Verena Roloff, Michael Hallek, Andreas Engert |
| Abstract |
Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in Western countries. Standard treatment includes mono- or poly-chemotherapies. Nowadays, monoclonal antibodies are added, especially alemtuzumab and rituximab. However, the impact of these agents remains unclear, as there are hints of an increased risk of severe infections. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 176 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| France | 1 | <1% |
| Unknown | 173 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 24 | 14% |
| Other | 17 | 10% |
| Researcher | 17 | 10% |
| Student > Bachelor | 17 | 10% |
| Student > Ph. D. Student | 16 | 9% |
| Other | 36 | 20% |
| Unknown | 49 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 64 | 36% |
| Agricultural and Biological Sciences | 14 | 8% |
| Nursing and Health Professions | 10 | 6% |
| Psychology | 8 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Other | 21 | 12% |
| Unknown | 54 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2019.
All research outputs
#17,579,816
of 25,774,185 outputs
Outputs from Cochrane database of systematic reviews
#11,621
of 13,139 outputs
Outputs of similar age
#177,398
of 259,901 outputs
Outputs of similar age from Cochrane database of systematic reviews
#167
of 216 outputs
Altmetric has tracked 25,774,185 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,139 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.9. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 259,901 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 216 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.